Related Stories
![Area privada5](https://udic.es/wp-content/uploads/2017/11/Area-privada5-262x201.jpg)
16 de January de 2023
On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer’s…
![Area privada1](https://udic.es/wp-content/uploads/2017/11/Area-privada1-262x201.jpg)
3 de June de 2021
The General University Hospital of Catalonia is the first recognized center in Europe to evaluate…
Posted in: Alzeimer, Uncategorised
![Blogudic1](https://udic.es/wp-content/uploads/2019/03/Blogudic1-262x201.jpg)
![logo](https://udic.es/wp-content/uploads/2017/07/logo.png)
22 de July de 2020
The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson’s…
Posted in: Parkinson, Uncategorised
![Proyectos2](https://udic.es/wp-content/uploads/2017/11/Proyectos2-262x201.jpg)
12 de December de 2019
![UDICEQUIPOMEDICO3](https://udic.es/wp-content/uploads/2018/11/UDICEQUIPOMEDICO3-262x201.jpg)
5 de November de 2019
The Pasqual Maragall Foundation develops a method based on magnetic resonance imaging It allows to…
Posted in: Alzeimer, Uncategorised
![logo](https://udic.es/wp-content/uploads/2017/07/logo.png)
19 de July de 2019
We have been selected to evaluate an innovative therapy in this terrible disease. We will…
Posted in: Uncategorised
![montaje udic patkinson](https://udic.es/wp-content/uploads/2019/03/montaje-udic-patkinson-262x201.jpg)
20 de March de 2019
The UDIC will shortly begin a clinical trial to evaluate the subcutaneous administration of levodopa,…
Posted in: Uncategorised